1. Indications:

Tractoni (Larotrectinib) 100 mg is indicated for the treatment of:

• Adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation.
• Patients with locally advanced or metastatic solid tumors that are NTRK fusion-positive and have progressed following treatment, or who have no satisfactory alternative treatments.

2. Pharmacology:

Tractoni (Larotrectinib) 100 mg exerts its pharmacological effects by selectively inhibiting the activity of tropomyosin receptor kinase (TRK) proteins, which are encoded by neurotrophic tyrosine receptor kinase (NTRK) genes. By inhibiting TRK proteins, Larotrectinib interferes with signaling pathways involved in cancer cell proliferation and survival, ultimately leading to tumor regression and inhibition of cancer progression.

3. Dosage and Administration:

The recommended dosage of Tractoni (Larotrectinib) 100 mg may vary depending on patient characteristics and tumor response. Typically, the prescribed dose is 100 mg taken orally twice daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity occurs. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Tractoni (Larotrectinib) 100 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Larotrectinib.
• Acid-reducing agents: Concurrent use of proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease the absorption of Larotrectinib, potentially reducing its efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Tractoni (Larotrectinib) 100 mg may include:

• Fatigue
• Nausea
• Dizziness
• Vomiting
• Diarrhea
• Increased liver enzymes

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Tractoni (Larotrectinib) 100 mg, patients should be aware of the following precautions:

• Larotrectinib may cause hepatotoxicity, including liver function abnormalities. Liver function tests should be performed before starting treatment and periodically thereafter.
• Cardiovascular adverse reactions, including QT interval prolongation, have been reported with Larotrectinib. Electrocardiograms (ECGs) should be monitored regularly, especially in patients with pre-existing cardiac conditions.
• Larotrectinib may cause fetal harm if used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least one week after the last dose.

7. Overdose Effects:

In case of overdose with Tractoni (Larotrectinib) 100 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Larotrectinib overdose, and patients should seek immediate medical attention if overdose is suspected.